Gut microbiota dysbiosis driven by pathogenic and opportunistic bacteria, including Clostridioides difficile, adherent-invasive Escherichia coli (AIEC), Salmonella enterica serovar Typhimurium, Fusobacterium nucleatum, Klebsiella pneumoniae, Enterococcus faecalis, and Campylobacter spp., disrupts colonization resistance, epithelial barrier integrity, and immune homeostasis, thereby contributing to the development of inflammatory and metabolic diseases. In this review, we summarize the mechanisms through which these microorganisms promote gut dysbiosis and critically evaluate current microbiome-targeted therapeutic strategies, including fecal microbiota transplantation (FMT), live biotherapeutic products (LBPs), probiotics, and bacteriophage (phage) therapy. We review the preclinical and emerging clinical evidence supporting phage-based targeting of major dysbiosis-associated pathogens and examine the principal challenges limiting clinical translation, including phage resistance, immune-mediated clearance, safety considerations related to temperate phages, manufacturing and delivery constraints, and regulatory barriers. Although evidence remains predominantly preclinical, advances in phage engineering, artificial intelligence-guided phage selection, and systems-level microbiome modeling are expanding the potential of personalized phage therapeutics. Collectively, these developments position bacteriophage therapy as a promising addition to future microbiome-directed strategies for restoring gut microbial homeostasis and managing dysbiosis-associated disease.
Citation: Ahmed Dewan, Débora Brito Goulart, Maria Teresa Mascellino. Gut microbiota dysbiosis: Pathogenic drivers and emerging phage-based therapeutics[J]. AIMS Microbiology, 2026, 12(3): 632-665. doi: 10.3934/microbiol.2026028
Gut microbiota dysbiosis driven by pathogenic and opportunistic bacteria, including Clostridioides difficile, adherent-invasive Escherichia coli (AIEC), Salmonella enterica serovar Typhimurium, Fusobacterium nucleatum, Klebsiella pneumoniae, Enterococcus faecalis, and Campylobacter spp., disrupts colonization resistance, epithelial barrier integrity, and immune homeostasis, thereby contributing to the development of inflammatory and metabolic diseases. In this review, we summarize the mechanisms through which these microorganisms promote gut dysbiosis and critically evaluate current microbiome-targeted therapeutic strategies, including fecal microbiota transplantation (FMT), live biotherapeutic products (LBPs), probiotics, and bacteriophage (phage) therapy. We review the preclinical and emerging clinical evidence supporting phage-based targeting of major dysbiosis-associated pathogens and examine the principal challenges limiting clinical translation, including phage resistance, immune-mediated clearance, safety considerations related to temperate phages, manufacturing and delivery constraints, and regulatory barriers. Although evidence remains predominantly preclinical, advances in phage engineering, artificial intelligence-guided phage selection, and systems-level microbiome modeling are expanding the potential of personalized phage therapeutics. Collectively, these developments position bacteriophage therapy as a promising addition to future microbiome-directed strategies for restoring gut microbial homeostasis and managing dysbiosis-associated disease.
| [1] |
Mntambo N, Arumugam T, Pramchand A, et al. (2025) A review of global patterns in gut microbiota composition, health and disease: Locating South Africa in the conversation. Microorganisms 13: 2831. https://doi.org/10.3390/microorganisms13122831 
|
| [2] |
Sender R, Fuchs S, Milo R (2016) Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 14: e1002533. https://doi.org/10.1371/journal.pbio.1002533
|
| [3] |
Toor D, Wasson MK, Kumar P, et al. (2019) Dysbiosis disrupts gut immune homeostasis and promotes gastric diseases. Int J Mol Sci 20: 2432. https://doi.org/10.3390/ijms20102432
|
| [4] |
Petersen C, Round JL (2014) Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 16: 1024-1033. https://doi.org/10.1111/cmi.12308
|
| [5] |
Adak A, Khan MR (2019) An insight into gut microbiota and its functionalities. Cell Mol Life Sci 76: 473-493. https://doi.org/10.1007/s00018-018-2943-4
|
| [6] |
Ezenabor EH, Adeyemi AA, Adeyemi OS (2024) Gut microbiota and metabolic syndrome: Relationships and opportunities for new therapeutic strategies. Scientifica 2024: 4222083. https://doi.org/10.1155/2024/4222083
|
| [7] |
Valles-Colomer M, Falony G, Darzi Y, et al. (2019) The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 4: 623-632. https://doi.org/10.1038/s41564-018-0337-x
|
| [8] |
Simpson CA, Diaz-Arteche C, Eliby D, et al. (2021) The gut microbiota in anxiety and depression—A systematic review. Clin Psychol Rev 83: 101943. https://doi.org/10.1016/j.cpr.2020.101943
|
| [9] |
Usuda H, Okamoto T, Wada K (2021) Leaky gut: Effect of dietary fiber and fats on microbiome and intestinal barrier. Int J Mol Sci 22: 7613. https://doi.org/10.3390/ijms22147613
|
| [10] |
Shkoporov AN, Hill C (2019) Bacteriophages of the human gut: The “known unknown” of the microbiome. Cell Host Microbe 25: 195-209. https://doi.org/10.1016/j.chom.2019.01.017
|
| [11] |
Lathakumari RH, Vajravelu LK, Gopinathan A, et al. (2025) The gut virome and human health: From diversity to personalized medicine. Eng Microbiol 5: 100191. https://doi.org/10.1016/j.engmic.2025.100191
|
| [12] |
Hsu BB, Gibson TE, Yeliseyev V, et al. (2019) Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. Cell Host Microbe 25: 803-814.e5. https://doi.org/10.1016/j.chom.2019.05.001
|
| [13] |
Gogokhia L, Buhrke K, Bell R, et al. (2019) Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host Microbe 25: 285-299.e8. https://doi.org/10.1016/j.chom.2019.01.008
|
| [14] |
Nakatsu G, Zhou H, Wu WKK, et al. (2018) Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology 155: 529-541. https://doi.org/10.1053/j.gastro.2018.04.018
|
| [15] |
Liang G, Bushman FD (2021) The human virome: Assembly, composition and host interactions. Nat Rev Microbiol 19: 514-527. https://doi.org/10.1038/s41579-021-00536-5
|
| [16] |
Lin Y, Lu P, Ding Q, et al. (2026) Current perspectives on the inflammatory bowel disease pathogenesis of microbiota and the gut-brain axis, and emerging therapeutics. Biomedicines 14: 859. https://doi.org/10.3390/biomedicines14040859
|
| [17] |
Gillis CC, Hughes ER, Spiga L, et al. (2018) Dysbiosis-associated change in host metabolism generates lactate to support Salmonella growth. Cell Host Microbe 23: 54-64.e6. https://doi.org/10.1016/j.chom.2017.11.006
|
| [18] |
Jiang Q, Xu Q, Kenéz Á, et al. (2022) Klebsiella pneumoniae infection is associated with alterations in the gut microbiome and lung metabolome. Microbiol Res 263: 127139. https://doi.org/10.1016/j.micres.2022.127139
|
| [19] |
Madani WAM, Ramos Y, Cubillos-Ruiz JR, et al. (2024) Enterococcal-host interactions in the gastrointestinal tract and beyond. FEMS Microbes 5: xtae027. https://doi.org/10.1093/femsmc/xtae027
|
| [20] |
Jalanka J, Gunn D, Singh G, et al. (2023) Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery. Gut 72: 451-459. https://doi.org/10.1136/gutjnl-2021-326828
|
| [21] |
Cammarota G, Ianiro G, Tilg H, et al. (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66: 569-580. https://doi.org/10.1136/gutjnl-2016-313017
|
| [22] |
Khanna S, Pardi DS, Kelly CR, et al. (2016) A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 214: 173-181. https://doi.org/10.1093/infdis/jiv766
|
| [23] |
Cordaillat-Simmons M, Rouanet A, Pot B (2020) Live biotherapeutic products: The importance of a defined regulatory framework. Exp Mol Med 52: 1397-1406. https://doi.org/10.1038/s12276-020-0437-6
|
| [24] |
Olle B (2013) Medicines from microbiota. Nat Biotechnol 31: 309-315. https://doi.org/10.1038/nbt.2548
|
| [25] |
Emencheta SC, Olovo CV, Eze OC, et al. (2023) The role of bacteriophages in the gut microbiota: Implications for human health. Pharmaceutics 15: 2416. https://doi.org/10.3390/pharmaceutics15102416
|
| [26] |
Górski A, Międzybrodzki R, Węgrzyn G, et al. (2020) Phage therapy: Current status and perspectives. Med Res Rev 40: 459-463. https://doi.org/10.1002/med.21593
|
| [27] |
Federici S, Nobs SP, Elinav E (2021) Phages and their potential to modulate the microbiome and immunity. Cell Mol Immunol 18: 889-904. https://doi.org/10.1038/s41423-020-00532-4
|
| [28] |
Duan Y, Young R, Schnabl B (2022) Bacteriophages and their potential for treatment of gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 19: 135-144. https://doi.org/10.1038/s41575-021-00536-z
|
| [29] |
Thursby E, Juge N (2017) Introduction to the human gut microbiota. Biochem J 474: 1823-1836. https://doi.org/10.1042/BCJ20160510
|
| [30] |
Buffie CG, Bucci V, Stein RR, et al. (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517: 205-208. https://doi.org/10.1038/nature13828
|
| [31] |
Theriot CM, Koenigsknecht MJ, Carlson PE, et al. (2014) Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5: 3114. https://doi.org/10.1038/ncomms4114
|
| [32] |
Seekatz AM, Young VB (2014) Clostridium difficile and the microbiota. J Clin Invest 124: 4182-4189. https://doi.org/10.1172/JCI72336
|
| [33] |
Sorg JA, Sonenshein AL (2008) Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190: 2505-2512. https://doi.org/10.1128/jb.01765-07
|
| [34] |
Voth DE, Ballard JD (2005) Clostridium difficile toxins: Mechanism of action and role in disease. Clin Microbiol Rev 18: 247-263. https://doi.org/10.1128/cmr.18.2.247-263.2005
|
| [35] |
Chandrasekaran R, Lacy DB (2017) The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev 41: 723-750. https://doi.org/10.1093/femsre/fux048
|
| [36] | Richard JF, Petit L, Gibert M, et al. (1999) Bacterial toxins modifying the actin cytoskeleton. Int Microbiol 2: 185-194. |
| [37] |
Cowardin CA, Buonomo EL, Saleh MM, et al. (2016) The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nat Microbiol 1: 16108. https://doi.org/10.1038/nmicrobiol.2016.108
|
| [38] |
Buffie CG, Pamer EG (2013) Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 13: 790-801. https://doi.org/10.1038/nri3535
|
| [39] |
Theriot CM, Bowman AA, Young VB (2016) Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere 1: 10-1128. https://doi.org/10.1128/msphere.00045-15
|
| [40] |
Galán JE (2009) Common themes in the design and function of bacterial effectors. Cell Host Microbe 5: 571-579. https://doi.org/10.1016/j.chom.2009.04.008
|
| [41] |
McGhie EJ, Brawn LC, Hume PJ, et al. (2009) Salmonella takes control: Effector-driven manipulation of the host. Curr Opin Microbiol 12: 117-124. https://doi.org/10.1016/j.mib.2008.12.001
|
| [42] |
Hapfelmeier S, Stecher B, Barthel M, et al. (2005) The Salmonella pathogenicity island (SPI)-2 and SPI-1 type III secretion systems allow Salmonella serovar typhimurium to trigger colitis via MyD88-dependent and MyD88-independent mechanisms. J Immunol 174: 1675-1685. https://doi.org/10.4049/jimmunol.174.3.1675
|
| [43] | Lawrence ALE, Abuaita BH, Berger RP, et al. (2021) Salmonella enterica serovar typhimurium SPI-1 and SPI-2 shape the global transcriptional landscape in a human intestinal organoid model system. mBio 12: 10-1128. https://doi.org/10.1128/mbio.00399-21 |
| [44] |
Eckmann L, Kagnoff MF (2001) Cytokines in host defense against Salmonella. Microbes Infect 3: 1191-1200. https://doi.org/10.1016/S1286-4579(01)01479-4
|
| [45] |
Huang FC (2021) The interleukins orchestrate mucosal immune responses to salmonella infection in the intestine. Cells 10: 3492. https://doi.org/10.3390/cells10123492
|
| [46] |
Thiennimitr P, Winter SE, Winter MG, et al. (2011) Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota. Proc Natl Acad Sci USA 108: 17480-17485. https://doi.org/10.1073/pnas.1107857108
|
| [47] |
Winter SE, Thiennimitr P, Winter MG, et al. (2010) Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature 467: 426-429. https://doi.org/10.1038/nature09415
|
| [48] |
Ginzberg HH, Cherapanov V, Dong Q, et al. (2001) Neutrophil-mediated epithelial injury during transmigration: Role of elastase. Am J Physiol Gastrointest Liver Physiol 281: G705-G717. https://doi.org/10.1152/ajpgi.2001.281.3.G705
|
| [49] |
Zha L, Garrett S, Sun J (2019) Salmonella infection in chronic inflammation and gastrointestinal cancer. Diseases 7: 28. https://doi.org/10.3390/diseases7010028
|
| [50] |
Zeng MY, Inohara N, Nuñez G (2017) Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol 10: 18-26. https://doi.org/10.1038/mi.2016.75
|
| [51] |
Stecher B, Robbiani R, Walker AW, et al. (2007) Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 5: e244. https://doi.org/10.1371/journal.pbio.0050244
|
| [52] |
Winter SE, Bäumler AJ (2014) Why related bacterial species bloom simultaneously in the gut: Principles underlying the ‘Like will to like’ concept. Cell Microbiol 16: 179-184. https://doi.org/10.1111/cmi.12245
|
| [53] |
Rigottier-Gois L (2013) Dysbiosis in inflammatory bowel diseases: The oxygen hypothesis. Isme J 7: 1256-1261. https://doi.org/10.1038/ismej.2013.80
|
| [54] |
Darfeuille-Michaud A, Boudeau J, Bulois P, et al. (2004) High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127: 412-421. https://doi.org/10.1053/j.gastro.2004.04.061
|
| [55] |
Palmela C, Chevarin C, Xu Z, et al. (2018) Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut 67: 574-587. https://doi.org/10.1136/gutjnl-2017-314903
|
| [56] |
Barnich N, Darfeuille-Michaud A (2007) Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol 23: 16-20. https://doi.org/10.1097/MOG.0b013e3280105a38
|
| [57] |
Martinez-Medina M, Garcia-Gil LJ (2014) Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol 5: 213. https://doi.org/10.4291/wjgp.v5.i3.213
|
| [58] |
Carvalho FA, Barnich N, Sivignon A, et al. (2009) Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 206: 2179-2189. https://doi.org/10.1084/jem.20090741
|
| [59] |
Barnich N, Carvalho FA, Glasser AL, et al. (2007) CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 117: 1566-1574. https://doi.org/10.1172/JCI30504
|
| [60] |
Glasser AL, Boudeau J, Barnich N, et al. (2001) Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 69: 5529-5537. https://doi.org/10.1128/iai.69.9.5529-5537.2001
|
| [61] |
Bringer MA, Glasser AL, Tung CH, et al. (2006) The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell Microbiol 8: 471-484. https://doi.org/10.1111/j.1462-5822.2005.00639.x
|
| [62] |
Shawki A, McCole DF (2017) Mechanisms of intestinal epithelial barrier dysfunction by adherent-invasive Escherichia coli. Cell Mol Gastroenterol Hepatol 3: 41-50. https://doi.org/10.1016/j.jcmgh.2016.10.004
|
| [63] |
Wine E, Ossa JC, Gray-Owen SD, et al. (2010) Adherent-invasive Escherichia coli target the epithelial barrier. Gut Microbes 1: 80-84. https://doi.org/10.4161/gmic.1.2.11142
|
| [64] |
Sokol H, Pigneur B, Watterlot L, et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci 105: 16731-16736. https://doi.org/10.1073/pnas.0804812105
|
| [65] |
Castellarin M, Warren RL, Freeman JD, et al. (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22: 299-306. https://doi.org/10.1101/gr.126516.111
|
| [66] |
Rubinstein MR, Wang X, Liu W, et al. (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14: 195-206. https://doi.org/10.1016/j.chom.2013.07.012
|
| [67] |
Kostic AD, Chun E, Robertson L, et al. (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14: 207-215. https://doi.org/10.1016/j.chom.2013.07.007
|
| [68] |
Brennan CA, Clay SL, Lavoie SL, et al. (2021) Fusobacterium nucleatum drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression. Gut Microbes 13: 1987780. https://doi.org/10.1080/19490976.2021.1987780
|
| [69] |
Yang Y, Weng W, Peng J, et al. (2017) Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 Signaling to nuclear factor-κB, and up-regulating expression of microRNA-21. Gastroenterology 152: 851-866.e24. https://doi.org/10.1053/j.gastro.2016.11.018
|
| [70] |
Hu Y, Yang Y, Li Y, et al. (2025) Th17/Treg imbalance in inflammatory bowel disease: Immunological mechanisms and microbiota-driven regulation. Front Immunol 16: 1651063. https://doi.org/10.3389/fimmu.2025.1651063
|
| [71] |
Chen L, Ruan G, Cheng Y, et al. (2022) The role of Th17 cells in inflammatory bowel disease and the research progress. Front Immunol 13: 1055914. https://doi.org/10.3389/fimmu.2022.1055914
|
| [72] |
Yang X, Zhang S, Ning T, et al. (2025) Fusobacterium nucleatum in health and disease. MedComm 6: e70465. https://doi.org/10.1002/mco2.70465
|
| [73] |
Wu QL, Fang XT, Wan XX, et al. (2024) Fusobacterium nucleatum-induced imbalance in microbiome-derived butyric acid levels promotes the occurrence and development of colorectal cancer. World J Gastroenterol 30: 2018-2037. https://doi.org/10.3748/wjg.v30.i14.2018
|
| [74] |
Sanjana A, Viswanathan P (2026) From dysbiosis to tumorigenesis: Microbiome-derived metabolites as emerging cancer biomarkers. Front Microbiol 17: 1843755. https://doi.org/10.3389/fmicb.2026.1843755
|
| [75] |
Gur C, Ibrahim Y, Isaacson B, et al. (2015) Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42: 344-355. https://doi.org/10.1016/j.immuni.2015.01.010
|
| [76] |
Srivastava S, Kumar S (2025) Microbial oncogenesis: The impact of Fusobacterium nucleatum on oral cancer pathways. Med Oncol 43: 18. https://doi.org/10.1007/s12032-025-03150-0
|
| [77] |
Abed J, Emgård JEM, Zamir G, et al. (2016) Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 20: 215-225. https://doi.org/10.1016/j.chom.2016.07.006
|
| [78] | Zhao T, Wang X, Fu L, et al. (2022) Fusobacterium nucleatum: A new player in regulation of cancer development and therapeutic response. Cancer Drug Resist 5: 436-450. https://doi.org/10.20517/cdr.2021.144 |
| [79] |
Yu T, Guo F, Yu Y, et al. (2017) Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170: 548-563. https://doi.org/10.1016/j.cell.2017.07.008
|
| [80] |
Gethings-Behncke C, Coleman HG, Jordao HWT, et al. (2020) Fusobacterium nucleatum in the colorectum and its association with cancer risk and survival: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 29: 539-548. https://doi.org/10.1158/1055-9965.EPI-18-1295
|
| [81] |
Huangfu SC, Zhang WB, Zhang HR, et al. (2021) Clinicopathological and prognostic significance of Fusobacterium nucleatum infection in colorectal cancer: A meta-analysis. J Cancer 12: 1583-1591. https://doi.org/10.7150/jca.50111
|
| [82] |
Zhang Q, Su X, Zhang C, et al. (2023) Klebsiella pneumoniae induces inflammatory bowel disease through caspase-11–mediated IL18 in the gut epithelial cells. Cell Mol Gastroenterol Hepatol 15: 613-632. https://doi.org/10.1016/j.jcmgh.2022.11.005
|
| [83] |
Yang Y, van Schaik W, McNally A, et al. (2026) Microbiome-mediated colonization resistance to and countermeasures of Klebsiella pneumoniae. Nat Commun 17: 1761. https://doi.org/10.1038/s41467-026-69690-9
|
| [84] |
Bray AS, Zafar MA (2024) Deciphering the gastrointestinal carriage of Klebsiella pneumoniae. Infect Immun 92: e00482-23. https://doi.org/10.1128/iai.00482-23
|
| [85] |
Deng J, Cheng L, Liu J, et al. (2026) Molecular and mechanistic insights into the gut-liver axis in K. pneumoniae infections: Current advances and future directions. Infect Immun 94: e00477-25. https://doi.org/10.1128/iai.00477-25
|
| [86] |
Regueiro V, Moranta D, Campos MA, et al. (2009) Klebsiella pneumoniae increases the levels of Toll-like receptors 2 and 4 in human airway epithelial cells. Infect Immun 77: 714-724. https://doi.org/10.1128/iai.00852-08
|
| [87] |
Abbas R, Chakkour M, Zein El Dine H, et al. (2024) General overview of Klebsiella pneumonia: Epidemiology and the role of siderophores in its pathogenicity. Biology 13: 78. https://doi.org/10.3390/biology13020078
|
| [88] |
Ling Z, Ding W, Liu X, et al. (2025) Gut microbiota dysbiosis and systemic immune dysfunction in critical ill patients with multidrug-resistant bacterial colonization and infection. J Transl Med 23: 981. https://doi.org/10.1186/s12967-025-07049-2
|
| [89] | Dubin K, Pamer EG (2014) Enterococci and their interactions with the intestinal microbiome. Microbiol Spectr 5: 10-1128. https://doi.org/10.1128/microbiolspec.bad-0014-2016 |
| [90] |
Steck N, Hoffmann M, Sava IG, et al. (2011) Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology 141: 959-971. https://doi.org/10.1053/j.gastro.2011.05.035
|
| [91] |
Franz CMAP, Huch M, Abriouel H, et al. (2011) Enterococci as probiotics and their implications in food safety. Int J Food Microbiol 151: 125-140. https://doi.org/10.1016/j.ijfoodmicro.2011.08.014
|
| [92] |
Arias CA, Murray BE (2012) The rise of the Enterococcus: Beyond vancomycin resistance. Nat Revi Microbiol 10: 266-278. https://doi.org/10.1038/nrmicro2761
|
| [93] |
Goh HMS, Yong MHA, Chong KKL, et al. (2017) Model systems for the study of Enterococcal colonization and infection. Virulence 8: 1525-1562. https://doi.org/10.1080/21505594.2017.1279766
|
| [94] |
Repoila F, Le Bohec F, Guérin C, et al. (2022) Adaptation of the gut pathobiont Enterococcus faecalis to deoxycholate and taurocholate bile acids. Sci Rep 12: 8485. https://doi.org/10.1038/s41598-022-12552-3
|
| [95] |
Kemper L, Hensel A (2023) Campylobacter jejuni: Targeting host cells, adhesion, invasion, and survival. Appl Microbiol Biotechnol 107: 2725-2754. https://doi.org/10.1007/s00253-023-12456-w
|
| [96] | Konkel ME, Monteville MR, Rivera-Amill V, et al. (2001) The pathogenesis of Campylobacter jejuni-mediated enteritis. Curr Issues Intest Microbiol 2: 55-71. Available from: https://www.caister.com/backlist/ciim/v/v2/05.pdf |
| [97] | Heimesaat MM, Backert S, Alter T, et al. (2021) Human campylobacteriosis—A serious infectious threat in a one health perspective. Fighting Campylobacter Infections . Cham: Springer 1-23. https://doi.org/10.1007/978-3-030-65481-8_1 |
| [98] |
Kalischuk LD, Buret AG (2010) A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease?. Am J Physiol Gastrointest Liver Physiol 298: G1-G9. https://doi.org/10.1152/ajpgi.00193.2009
|
| [99] |
Boehm M, Simson D, Escher U, et al. (2018) Function of serine protease HtrA in the lifecycle of the foodborne pathogen Campylobacter jejuni. Eur J Microbiol Immunol 8: 70-77. https://doi.org/10.1556/1886.2018.00011
|
| [100] |
Kampmann C, Dicksved J, Engstrand L, et al. (2016) Composition of human faecal microbiota in resistance to Campylobacter infection. Clin Microbiol Infect 22: 61.e1-61.e8. https://doi.org/10.1016/j.cmi.2015.09.004
|
| [101] |
Ramirez J, Guarner F, Bustos Fernandez L, et al. (2020) Antibiotics as major disruptors of gut microbiota. Fron Cell Infect Microbiol 10: 572912. https://doi.org/10.3389/fcimb.2020.572912
|
| [102] |
Langdon A, Crook N, Dantas G (2016) The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 8: 39. https://doi.org/10.1186/s13073-016-0294-z
|
| [103] |
Yassour M, Vatanen T, Siljander H, et al. (2016) Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci Transl Med 8: 343ra81-343ra81. https://doi.org/10.1126/scitranslmed.aad0917
|
| [104] |
Palleja A, Mikkelsen KH, Forslund SK, et al. (2018) Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol 3: 1255-1265. https://doi.org/10.1038/s41564-018-0257-9
|
| [105] |
Slimings C, Riley TV (2014) Antibiotics and hospital-acquired Clostridium difficile infection: Update of systematic review and meta-analysis. J Antimicrob Chemother 69: 881-891. https://doi.org/10.1093/jac/dkt477
|
| [106] |
Razik R, Rumman A, Bahreini Z, et al. (2016) Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: The RECIDIVISM study. Am J Gastroenterol 111: 1141-1146. https://doi.org/10.1038/ajg.2016.187
|
| [107] |
Leffler DA, Lamont JT (2015) Clostridium difficile infection. N Engl J Med 372: 1539-1548. https://doi.org/10.1056/NEJMra1403772
|
| [108] |
Song JH, Kim YS (2019) Recurrent Clostridium difficile infection: Risk factors, treatment, and prevention. Gut Liver 13: 16. https://doi.org/10.5009/gnl18071
|
| [109] |
Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 108: 4554-4561. https://doi.org/10.1073/pnas.1000087107
|
| [110] |
Mullish BH, McDonald JAK, Pechlivanis A, et al. (2019) Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut 68: 1791-1800. https://doi.org/10.1136/gutjnl-2018-317842
|
| [111] |
van Nood E, Vrieze A, Nieuwdorp M, et al. (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368: 407-415. https://doi.org/10.1056/NEJMoa1205037
|
| [112] |
Ooijevaar RE, Terveer EM, Verspaget HW, et al. (2019) Clinical application and potential of fecal microbiota transplantation. Annu Rev Med 70: 335-351. https://doi.org/10.1146/annurev-med-111717-122956
|
| [113] |
Quiroga-Centeno AC, Atanasova K, Ebert MP, et al. (2025) Emerging microbiome-directed therapies in inflammatory bowel disease: Beyond diet modification and FMT. Semin Immunopathol 47: 42. https://doi.org/10.1007/s00281-025-01066-5
|
| [114] |
Elendu C, Omeludike EK, Aregbesola ET, et al. (2025) Fecal microbiota transplantation as a therapeutic modality for recurrent Clostridioides difficile infection: Reviewing efficacy, safety, mechanisms of action, and outcomes. Ann Med Surg 87: 5829. https://doi.org/10.1097/MS9.0000000000003649
|
| [115] |
Merrick B, Allen L, Masirah MZN, et al. (2020) Regulation, risk and safety of Faecal Microbiota Transplant. Infect Prev Pract 2: 100069. https://doi.org/10.1016/j.infpip.2020.100069
|
| [116] | Food and Drug AdministrationSafety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms (2020). Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse-events-likely |
| [117] |
Millan B, Laffin M, Madsen K (2017) Fecal microbiota transplantation: Beyond Clostridium difficile. Curr Infect Dis Rep 19: 31. https://doi.org/10.1007/s11908-017-0586-5
|
| [118] |
Tseng CH, Wong S, Yu J, et al. (2025) Development of live biotherapeutic products: A position statement of Asia-Pacific Microbiota Consortium. Gut 74: 706-713. https://doi.org/10.1136/gutjnl-2024-334501
|
| [119] |
Min H, Choi KS, Yun S, et al. (2025) Live biotherapeutic products for metabolic diseases: Development strategies, challenges, and future directions. J Microbiol Biotechnol 35: e2410054. https://doi.org/10.4014/jmb.2410.10054
|
| [120] |
DuPont HL, DuPont AW, Tillotson GS (2024) Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. Ther Adv Gastroenterol 17: 17562848241253089. https://doi.org/10.1177/17562848241253089
|
| [121] |
Verdugo-Meza A, Chiang HM, Mayer EA, et al. (2025) Not quite a cure yet: Unlocking the unfulfilled promise of live biotherapeutics for disease treatment. Front Pharmacol 16: 1695976. https://doi.org/10.3389/fphar.2025.1695976
|
| [122] |
Andrade JC, Almeida D, Domingos M, et al. (2020) Commensal obligate anaerobic bacteria and health: Production, storage, and delivery strategies. Front Bioeng Biotechnol 8: 550. https://doi.org/10.3389/fbioe.2020.00550
|
| [123] |
McChalicher CWJ, Auniņš JG (2022) Drugging the microbiome and bacterial live biotherapeutic consortium production. Curr Opin Biotechnol 78: 102801. https://doi.org/10.1016/j.copbio.2022.102801
|
| [124] |
Qiu K, Anselmo AC (2021) Batch culture formulation of live biotherapeutic products. Adv Ther 4: 2000226. https://doi.org/10.1002/adtp.202000226
|
| [125] |
Kim DY, Lee SY, Lee JY, et al. (2024) Gut microbiome therapy: Fecal microbiota transplantation vs live biotherapeutic products. Gut Microbes 16: 2412376. https://doi.org/10.1080/19490976.2024.2412376
|
| [126] |
Ducarmon QR, Kuijper EJ, Olle B (2021) Opportunities and challenges in development of live biotherapeutic products to fight infections. J Infect Dis 223: S283-S289. https://doi.org/10.1093/infdis/jiaa779
|
| [127] |
Hill C, Guarner F, Reid G, et al. (2014) The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11: 506-514. https://doi.org/10.1038/nrgastro.2014.66
|
| [128] |
Gou HZ, Zhang YL, Ren LF, et al. (2022) How do intestinal probiotics restore the intestinal barrier?. Front Microbiol 13: 929346. https://doi.org/10.3389/fmicb.2022.929346
|
| [129] |
Zhang Y, Zhu X, Yu X, et al. (2023) Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy. Front Nutr 10: 1120168. https://doi.org/10.3389/fnut.2023.1120168
|
| [130] |
McFarland LV, Evans CT, Goldstein EJC (2018) Strain-specificity and disease-specificity of probiotic efficacy: A systematic review and meta-analysis. Front Med 5: 124. https://doi.org/10.3389/fmed.2018.00124
|
| [131] |
McFarland LV (2015) From yaks to yogurt: The history, development, and current use of probiotics. Clin Infect Dis 60: S85-S90. https://doi.org/10.1093/cid/civ054
|
| [132] |
Suez J, Zmora N, Segal E, et al. (2019) The pros, cons, and many unknowns of probiotics. Nat Med 25: 716-729. https://doi.org/10.1038/s41591-019-0439-x
|
| [133] |
Morelli L, Pellegrino P (2021) A critical evaluation of the factors affecting the survival and persistence of beneficial bacteria in healthy adults. Benef Microbes 12: 321-332. https://doi.org/10.3920/BM2021.0017
|
| [134] |
Kristensen NB, Bryrup T, Allin KH, et al. (2016) Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: A systematic review of randomized controlled trials. Genome Med 8: 52. https://doi.org/10.1186/s13073-016-0300-5
|
| [135] |
Kim YS, Choi SC (2023) The long and winding road to the best clinical research and personalized therapy with probiotics: Do not forget host physiology. J Neurogastroenterol Motil 29: 129-131. https://doi.org/10.5056/jnm23034
|
| [136] |
Kortright KE, Chan BK, Koff JL, et al. (2019) Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25: 219-232. https://doi.org/10.1016/j.chom.2019.01.014
|
| [137] |
Young R, Gill JJ (2015) Phage therapy redux—What is to be done?. Science 350: 1163-1164. https://doi.org/10.1126/science.aad6791
|
| [138] |
Williams NT (2010) Probiotics. Am J Health Syst Pharm 67: 449-458. https://doi.org/10.2146/ajhp090168
|
| [139] | Turner PE, Azeredo J, Buurman ET, et al. (2024) Addressing the research and development gaps in modern phage therapy. Phage 5: 30-39. https://doi.org/10.1089/phage.2023.0045.correx |
| [140] |
Goh S, Riley TV, Chang BJ (2005) Isolation and characterization of temperate bacteriophages of Clostridium difficile. Appl Environ Microbiol 71: 1079-1083. https://doi.org/10.1128/AEM.71.2.1079-1083.2005
|
| [141] |
Govind R, Fralick JA, Rolfe RD (2006) Genomic organization and molecular characterization of Clostridium difficile bacteriophage PhiCD119. J Bacteriol 188: 2568-2577. https://doi.org/10.1128/jb.188.7.2568-2577.2006
|
| [142] |
Fortier LC, Moineau S (2007) Morphological and genetic diversity of temperate phages in Clostridium difficile. Appl Environ Microbiol 73: 7358-7366. https://doi.org/10.1128/AEM.00582-07
|
| [143] |
Goh S, Ong PF, Song KP, et al. (2007) The complete genome sequence of Clostridium difficile phage phiC2 and comparisons to phiCD119 and inducible prophages of CD630. Microbiology 153: 676-685. https://doi.org/10.1099/mic.0.2006/002436-0
|
| [144] | Galtier M, De Sordi L, Sivignon A, et al. (2017) Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn's disease. J Crohns Colitis 11: 840-847. https://doi.org/10.1093/ecco-jcc/jjw224 |
| [145] |
Kabwe M, Brown TL, Dashper S, et al. (2019) Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting Fusobacterium nucleatum biofilms. Sci Rep 9: 9107. https://doi.org/10.1038/s41598-019-45549-6
|
| [146] |
Titécat M, Rousseaux C, Dubuquoy C, et al. (2022) Safety and efficacy of an AIEC-targeted bacteriophage cocktail in a mice colitis model. J Crohns Colitis 16: 1617-1627. https://doi.org/10.1093/ecco-jcc/jjac064
|
| [147] |
Federici S, Kredo-Russo S, Valdés-Mas R, et al. (2022) Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 185: 2879-2898.e24. https://doi.org/10.1016/j.cell.2022.07.003
|
| [148] |
Pelyuntha W, Yafa A, Ngasaman R, et al. (2022) Oral administration of a phage cocktail to reduce Salmonella Colonization in broiler gastrointestinal tract-A pilot study. Animals 12: 3087. https://doi.org/10.3390/ani12223087
|
| [149] |
Navez M, Antoine C, Laforêt F, et al. (2023) In vitro effect on piglet gut microbiota and in vivo assessment of newly isolated bacteriophages against F18 enterotoxigenic Escherichia coli (ETEC). Viruses 15: 1053. https://doi.org/10.3390/v15051053
|
| [150] |
Yang Y, Li R, Zhong Q, et al. (2025) In situ gut microbiota editing: Enhancing therapeutic efficacy for bacterial colitis by compatible oral hydrogel microspheres with phages. Nat Commun 16: 9785. https://doi.org/10.1038/s41467-025-65498-1
|
| [151] |
Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8: 317-327. https://doi.org/10.1038/nrmicro2315
|
| [152] |
Yehl K, Lemire S, Yang AC, et al. (2019) Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis. Cell 179: 459-469.e9. https://doi.org/10.1016/j.cell.2019.09.015
|
| [153] |
Tagliaferri TL, Jansen M, Horz HP (2019) Fighting pathogenic bacteria on two fronts: Phages and antibiotics as combined strategy. Front Cell Infect Microbiolog 9: 22. https://doi.org/10.3389/fcimb.2019.00022
|
| [154] |
Liu C, Hong Q, Chang RYK, et al. (2022) Phage–antibiotic therapy as a promising strategy to combat multidrug-resistant infections and to enhance antimicrobial efficiency. Antibiotics 11: 570. https://doi.org/10.3390/antibiotics11050570
|
| [155] |
Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25: 730-733. https://doi.org/10.1038/s41591-019-0437-z
|
| [156] |
Van Belleghem JD, Dąbrowska K, Vaneechoutte M, et al. (2018) Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses 11: 10. https://doi.org/10.3390/v11010010
|
| [157] |
Hodyra-Stefaniak K, Miernikiewicz P, Drapała J, et al. (2015) Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci Rep 5: 14802. https://doi.org/10.1038/srep14802
|
| [158] |
Barr JJ, Auro R, Furlan M, et al. (2013) Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci USA 110: 10771-10776. https://doi.org/10.1073/pnas.1305923110
|
| [159] |
Brüssow H, Canchaya C, Hardt WD (2004) Phages and the evolution of bacterial pathogens: From genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev 68: 560-602. https://doi.org/10.1128/mmbr.68.3.560-602.2004
|
| [160] |
Touchon M, Bernheim A, Rocha EPC (2016) Genetic and life-history traits associated with the distribution of prophages in bacteria. ISME J 10: 2744-2754. https://doi.org/10.1038/ismej.2016.47
|
| [161] |
Fortier LC, Sekulovic O (2013) Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4: 354-365. https://doi.org/10.4161/viru.24498
|
| [162] |
Malik DJ, Goncalves-Ribeiro H, GoldSchmitt D, et al. (2023) Advanced manufacturing, formulation and microencapsulation of therapeutic phages. Clin Infect Dis 77: S370-S383. https://doi.org/10.1093/cid/ciad555
|
| [163] |
Van Charante F, Holtappels D, Blasdel B, et al. (2021) Isolation of bacteriophages. Bacteriophages: Biology, Technology, Therapy . Springer 433-464. https://doi.org/10.1007/978-3-319-41986-2_14
|
| [164] |
Bretaudeau L, Tremblais K, Aubrit F, et al. (2020) Good manufacturing practice (GMP) compliance for phage therapy medicinal products. Front Microbiol 11: 1161. https://doi.org/10.3389/fmicb.2020.01161
|
| [165] |
Faltus T (2024) The medicinal phage—regulatory roadmap for phage therapy under EU pharmaceutical legislation. Viruses 16: 443. https://doi.org/10.3390/v16030443
|
| [166] |
Hyman P (2019) Phages for phage therapy: Isolation, characterization, and host range breadth. Pharmaceuticals 12: 35. https://doi.org/10.3390/ph12010035
|
| [167] | US Food and Drug AdministrationGuidance for Industry—Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice (2004). Available from: https://www.fda.gov/media/71026/download |
| [168] |
Niazi SK (2025) Bacteriophage therapy: Discovery, development, and FDA approval pathways. Pharmaceuticals 18: 1115. https://doi.org/10.3390/ph18081115
|
| [169] |
Kline A, Cobián Güemes AG, Yore J, et al. (2025) Current clinical laboratory challenges to widespread adoption of phage therapy in the United States. Antibiotics 14: 553. https://doi.org/10.3390/antibiotics14060553
|
| [170] |
Pelfrene E, Willebrand E, Cavaleiro Sanches A, et al. (2016) Bacteriophage therapy: A regulatory perspective. J Antimicrob Chemother 71: 2071-2074. https://doi.org/10.1093/jac/dkw083
|
| [171] |
Fauconnier A (2019) Phage therapy regulation: From night to dawn. Viruses 11: 352. https://doi.org/10.3390/v11040352
|
| [172] |
Zelasko S, Gorski A, Dabrowska K (2017) Delivering phage therapy per os: Benefits and barriers. Expert Rev Anti-Infect Ther 15: 167-179. https://doi.org/10.1080/14787210.2017.1265447
|
| [173] |
Häckl D, Dillschneider J, Elsner C (2025) Cost aspects and reimbursement requirements of phage therapy. Bundesgesundheitsbl 68: 653-659. https://doi.org/10.1007/s00103-025-04065-x
|
| [174] |
Fuerst-Wilmes M, Respondek V, Schramm M, et al. (2025) Regulation of phage therapy medicinal products: Developments, challenges, and opportunities. Front Cell Infect Microbiol 15: 1631359. https://doi.org/10.3389/fcimb.2025.1631359
|
| [175] |
Verbeken G, Pirnay JP, De Vos D, et al. (2012) Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp 60: 161-172. https://doi.org/10.1007/s00005-012-0175-0
|
| [176] |
Furfaro LL, Payne MS, Chang BJ (2018) Bacteriophage therapy: CLinical trials and regulatory hurdles. Front Cell Infect Microbiol 8: 376. https://doi.org/10.3389/fcimb.2018.00376
|
| [177] |
Fukaya-Shiba A, Ogata A, Kuribayashi R, et al. (2025) Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections. Front Pharmacol 16: 1713471. https://doi.org/10.3389/fphar.2025.1713471
|
| [178] |
Boeckaerts D, Stock M, Ferriol-González C, et al. (2024) Prediction of Klebsiella phage-host specificity at the strain level. Nat Commun 15: 4355. https://doi.org/10.1038/s41467-024-48675-6
|
| [179] |
Boeckaerts D, Stock M, Criel B, et al. (2021) Predicting bacteriophage hosts based on sequences of annotated receptor-binding proteins. Sci Rep 11: 1467. https://doi.org/10.1038/s41598-021-81063-4
|
| [180] |
Doud MB, Robertson JM, Strathdee SA (2025) Optimizing phage therapy with artificial intelligence: A perspective. Front Cell Infect Microbiol 15: 1611857. https://doi.org/10.3389/fcimb.2025.1611857
|
| [181] |
Mutalik VK, Adler BA, Rishi HS, et al. (2020) High-throughput mapping of the phage resistance landscape in E. coli. PLOS Biology 18: e3000877. https://doi.org/10.1371/journal.pbio.3000877
|
| [182] |
Alexandrescu L, Tofolean IT, Condur LM, et al. (2025) Smart microbiomes: How AI is revolutionizing personalized medicine. Bioengineering 12: 944. https://doi.org/10.3390/bioengineering12090944
|
| [183] |
Kim M, Gim D, Kim S, et al. (2025) From dysbiosis to prediction: AI-powered microbiome insights into IBD and CRC. Gastroenterol Insights 16: 34. https://doi.org/10.3390/gastroent16030034
|
| [184] |
Selle K, Fletcher JR, Tuson H, et al. (2020) In Vivo targeting of Clostridioides difficile using phage-delivered CRISPR-Cas3 antimicrobials. mBio 11. https://doi.org/10.1128/mbio.00019-20
|
| [185] |
Jia HJ, Jia PP, Yin S, et al. (2023) Engineering bacteriophages for enhanced host range and efficacy: Insights from bacteriophage-bacteria interactions. Front Microbiol 14: 1172635. https://doi.org/10.3389/fmicb.2023.1172635
|
| [186] |
Amarillas L, Chaidez C, González-Robles A, et al. (2016) Characterization of novel bacteriophage phiC119 capable of lysing multidrug-resistant Shiga toxin-producing Escherichia coli O157:H7. PeerJ 4: e2423. https://doi.org/10.7717/peerj.2423
|
| [187] |
Heinken A, Hertel J, Acharya G, et al. (2023) Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine. Nat Biotechnol 41: 1320-1331. https://doi.org/10.1038/s41587-022-01628-0
|
| [188] |
Quinn-Bohmann N, Wilmanski T, Sarmiento KR, et al. (2024) Microbial community-scale metabolic modelling predicts personalized short-chain fatty acid production profiles in the human gut. Nat Microbiol 9: 1700-1712. https://doi.org/10.1038/s41564-024-01728-4
|
| [189] |
Quinn-Bohmann N, Carr AV, Diener C, et al. (2025) Moving from genome-scale to community-scale metabolic models for the human gut microbiome. Nat Microbiol 10: 1055-1066. https://doi.org/10.1038/s41564-025-01972-2
|
| [190] |
Lerman JA, Hyduke DR, Latif H, et al. (2012) In silico method for modelling metabolism and gene product expression at genome scale. Nat Commun 3: 929. https://doi.org/10.1038/ncomms1928
|
| [191] |
Wang XW, Wang T, Liu YY (2026) Artificial intelligence for microbiology and microbiome research. Cell Syst 17: 101531. https://doi.org/10.1016/j.cels.2026.101531
|
| [192] |
Wu P, Li W, Zhang W, et al. (2025) Advanced strategies in phage research: Innovations, applications, and challenges. Microorganisms 13: 1960. https://doi.org/10.3390/microorganisms13081960
|
| [193] |
El Haddad L, Mendoza JF, Jobin C (2022) Bacteriophage-mediated manipulations of microbiota in gastrointestinal diseases. Front Microbiol 13: 1055427. https://doi.org/10.3389/fmicb.2022.1055427
|
| [194] |
Porter SB, Johnston BD, Kisiela D, et al. (2022) Bacteriophage cocktail and microcin-producing probiotic Escherichia coli protect mice against gut colonization with multidrug-resistant Escherichia coli sequence type 131. Front Microbiol 13: 887799. https://doi.org/10.3389/fmicb.2022.887799
|
| [195] |
Choi Y, Kang A, Seo E, et al. (2026) Combination of bacteriophage–probiotics alleviates intestinal barrier dysfunction by regulating gut microbiome in a chick model of multidrug-resistant Salmonella infection. J Anim Sci Biotechnol 17: 14. https://doi.org/10.1186/s40104-025-01324-4
|
Figures(4) / Tables(2)
Ahmed Dewan, Débora Brito Goulart, Maria Teresa Mascellino. Gut microbiota dysbiosis: Pathogenic drivers and emerging phage-based therapeutics[J]. AIMS Microbiology, 2026, 12(3): 632-665. doi: 10.3934/microbiol.2026028
DownLoad: